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The scientific rational for selection of surfactant type during oral formulation development 26 
requires an in-depth understanding of the interplay between surfactant characteristics and 27 
biopharmaceutical factors. Currently, however, there is a lack of comprehensive knowledge of 28 
how surfactant properties, such as hydrophilic-lipophilic balance (HLB), digestibility and fatty 29 
acid (FA) chain length, translate into in vivo performance. In the present study, the relationship 30 
between surfactant properties, in vitro characteristics and in vivo bioavailability was 31 
systematically evaluated. An in vitro lipolysis model was used to study the digestibility of a 32 
variety of non-ionic surfactants. Eight surfactants and one surfactant mixture were selected for 33 
further analysis using the model poorly water-soluble drug nilotinib. In vitro lipolysis of all 34 
nilotinib formulations was performed followed by an in vivo pharmacokinetic evaluation in 35 
rats. The in vitro lipolysis studies showed that medium chain FA based surfactants were more 36 
readily digested compared to long chain surfactants. The in vivo study demonstrated that a 37 
Tween 20 formulation significantly enhanced the absolute bioavailability of nilotinib up to 5.2-38 
fold relative to an aqueous suspension. In general, surfactants that were highly digestible in 39 
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vitro tended to display higher bioavailability of nilotinib in vivo. The bioavailability may 40 
additionally be related to the FA chain length of digestible surfactants with an improved 41 
exposure in the case of medium chain FA based surfactants. There was no apparent relationship 42 
between the HLB value of surfactants and the in vivo bioavailability of nilotinib. The impact 43 
of this study’s findings suggests that when designing surfactant-based formulations to enhance 44 
oral bioavailability of the poorly water-soluble drug nilotinib, highly digestible, medium chain-45 
based surfactants are preferred. Additionally, for low permeability drugs such as nilotinib, 46 
which is subject to efflux by intestinal P-glycoprotein, the biopharmaceutical effects of 47 
surfactants merit further consideration.  48 
 49 
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Many emerging drug candidates show poor solubility and/or permeability resulting in a low 62 
and variable oral bioavailability when administered in conventional dosage forms. 1 Therefore, 63 
there is a need to develop bio-enabling formulation technologies that enhance 64 
biopharmaceutical properties and improve oral absorption of these emerging drug candidates. 65 
2 The various bio-enabling approaches have been extensively reviewed including solid 66 
dispersions, 3, 4 lipid-based formulations 5 and nano-sized drug crystals/particles. 6 67 
Interestingly, one of the most common excipients included across most classes of bio-enabling 68 
approaches are surfactants, which, from a mechanistic perspective, can impart a variety of 69 
biopharmaceutical advantages including promoting supersaturation, 7, 8 enhancing 70 
solubilisation, 9 stabilisation of colloidal/nano-crystals, 10 increased dissolution rate 11 and 71 
increasing permeability. 12-16  72 
 73 
Surfactants can be classified according to the polar head group into ionic (cationic, anionic or 74 
zwitterionic) or non-ionic surfactants. 17 Non-ionic surfactants are considered favourable due 75 
to a low toxicity and a more readily maintained solubilising power under biorelevant 76 
conditions. 18 The most commonly used non-ionic surfactants are based on ethylene oxide / 77 
polyoxyethylene and referred to as ethoxylated surfactants e.g. sorbitan ester ethoxylates or 78 
fatty amine ethoxylates. 19 Other important non-ionic surfactant classes include polyol-based 79 
surfactants (e.g. glycoside, glycol or glycerol esters), amine oxides and sulfinyl surfactants. 19 80 
Ethoxylated and polyol surfactants can be further sub-classified into esters (e.g. glycol, 81 
glycerol, sorbitan, fatty acid ethoxylates) and ethers (e.g. poloxamers, ethoxylated fatty 82 
alcohol, alkyl phenol ethoxylates). For pharmaceutical applications ethoxylated and polyol 83 
esters and ethers such as Tweens (ethoxylated sorbitan esters) or Poloxamers (ethylene oxide-84 
propylene oxide copolymers) are widely utilised. As an excipient class, surfactants can exhibit 85 
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a diverse set of properties and characteristics, and hence a variety of physiochemical 86 
approaches have been applied for characterising surfactants. These include properties such as 87 
hydrophilic-lipophilic balance (HLB) value, molecular weight, chain length, molecular 88 
volume, critical micellar concentration (CMC), solubility parameters. 20 While many of these 89 
properties have been explored for a specific formulation approach, to date the selection of 90 
surfactants remains mostly empirically driven. Additionally, while many surfactants are 91 
derived from digestible fats and oils, the impact of digestion on surfactants is commonly not 92 
considered in formulation performance. However, digestibility of surfactants can impact many 93 
of the aforementioned physico-chemical properties of the excipient, as the chemical structure 94 
can change along the transit though the GIT. Furthermore, this illustrates the difficulty in 95 
developing a reliable surfactant classification system as properties of the surfactants may be 96 
influenced by in vivo conditions. 18 The present study aimed to address knowledge gaps in the 97 
literature on the relationships between surfactant properties and the biopharmaceutical 98 
performance in vivo. This study, therefore, provides a basis for establishing a performance-99 
based classification of surfactants in oral drug delivery.  100 
 101 
In addition to the solubility enhancing effects, surfactants can interact with lipid bilayer of cell 102 
membranes thereby increasing the permeability. 12 Furthermore, surfactants may influence pre-103 
systemic clearance of drugs by modulating transporters and metabolising enzymes. 13 For 104 
example, Tween 80 and Cremophor EL increased the uptake of digoxin, a P-glycoprotein (P-105 
gp) substrate, to the same extent as cyclosporin (a commonly used P-gp inhibitor), using the 106 
rat everted gut sac method. 14 This indicated that Cremophor EL and Polysorbate 80 can 107 
modulate P-gp to improve the bioavailability. Additionally, Pluronic F68, Labrasol, Brij 30 108 
and Tween 20 have also shown to be inhibitors of P-gp in vitro using the rat everted gut sac 109 
method or various cell lines. 15, 16 In addition to modulation of P-gp efflux activity, a number 110 
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of surfactants such as Tween 20, Cremophor EL, Pluronic F68 and Myrj S40 have 111 
demonstrated inhibitory effects on cytochrome P450 3A4 (CYP 3A4), 21 a key metabolic 112 
enzyme present in intestinal tissue. In the latter study, it was shown that among the tested 113 
surfactants Tween 20 showed the highest inhibition resulting in a significantly increased area 114 
under the curve (AUC) and a 40% decrease in AUC of the main metabolite of midazolam in 115 
rats. 21  116 
 117 
When considering the choice of digestible versus non-digestible surfactants, a key perceived 118 
advantage of non-digestible surfactants is in being ‘digestion-independent’ systems, and 119 
therefore in vitro characteristics can be readily employed to predict the likely performance in 120 
vivo. Additionally, digestible systems carry the risk that the surfactant may not serve the initial 121 
purpose in a post-digestive state. For example, digestion of surfactants may lead to a reduced 122 
solubilisation capacity of the colloidal aqueous dispersion and potentially lead to drug 123 
precipitation. However, studies have also suggested that digestion may in fact promote 124 
transient supersaturation in the intestinal media and therefore may promote absorption. 22 In 125 
addition, the released FA have shown to increase solubility of poorly soluble drugs as 126 
evidenced by in vitro measurements of solubility in assembled pre- and post-digestion media 127 
with lipid excipients. 23, 24 Moreover, free fatty acids (FFA) released post digestion may 128 
modulate the intestinal permeability. In several studies it was shown that the treatment of cells 129 
with medium chain FFA showed an increased paracellular transport via tight junction opening. 130 
25-30 In the case of unsaturated long chain FFA, in vitro cell experiments showed an increased 131 
membrane fluidity 31-33 as well as opened tight junctions. 26, 34 These biopharmaceutical effects 132 




There is currently a lack of comprehensive knowledge of how surfactant properties translate 135 
into in vivo bioavailability of poorly water-soluble drugs. The overarching goal of this study 136 
was to systematically explore the relationship between surfactant properties and in vivo 137 
performance, which will support a more science- and risk-based approach to surfactant 138 
selection in oral formulations. Nilotinib was chosen as a model poorly water-soluble drug for 139 
the study. Nilotinib is practically insoluble in buffer solutions of pH 4.5 and higher (pKa 2.1 140 
and 5.4), 35 is highly lipophilic (logP 4.95) as well as hydrophobic 24 and exhibits a moderate 141 
permeability across a confluent Caco-2 cell monolayer. 35, 36 Therefore, nilotinib was 142 
categorised as a class IV compound in the biopharmaceutical classification system (BCS). 143 
Nilotinib is predominantly metabolised by CYP 3A4 35 and is a P-gp substrate. 35-38 The pre-144 
systemic clearance is high with an AUC increase of 29% after co-administration of nilotinib 145 
with grapefruit juice (intestinal CYP 3A4 inhibitor). 39 The current commercial formulation, 146 
Tasigna®, is a capsule formulation containing the surfactant Pluronic F68 (poloxamer 188). 40 147 
The concentration and the scientific rational of the addition of Poloxamer 188 is unknown, 148 
however it has been reported that the use of surfactants did not increase the dissolution of 149 
nilotinib capsules at pH 4.5 and above. 36 The marketed formulation of nilotinib showed an 150 
absorption of ≥ 30% following a radiolabelled single 400 mg oral dose in humans. 41 151 
Additionally, preclinical studies in rats yielded an absolute bioavailability of 34% using a 152 
solution with Cremophor, dimethyl acetamide and 5% dextrose (20/10/70 (v/v/v)). 35 Using 153 
this as a model poorly water-soluble drug, the present study systematically assessed the impact 154 
of surfactant properties on oral bioavailability. Surfactants were classified according to FA 155 





MATERIALS AND METHODS 159 
Chemicals and materials 160 
Nilotinib and sorafenib were purchased from Kemprotec Ltd. (UK). Brij O2 (Polyoxyethylene 161 
(2) oleyl ether), Brij L23 (Polyoxyethylene (23) lauryl ether), Myrj S40 (Polyoxyethylene (40) 162 
stearate), Span 85 (Sorbitan trioleate), Span 80 (Sorbitan monooleate), Tween 80 163 
(Polyoxyethylene sorbitan monooleate) and Tween 20 (Polyoxyethylene sorbitan monolaurate) 164 
were kindly donated by Croda international Plc (UK). Lipoid E PC S (Phosphatidylcholine) 165 
was gifted by Lipoid GmbH (Germany). Taurodeoxycholic acid sodium salt (NaTDC), 166 
pancreatic lipase (8 x USP), Cremophor RH40 (Polyoxyl 40 hydrogenated castor oil) and 167 
Tween 85 (Polyoxyethylene sorbitan trioleate) were ordered from Sigma-Aldrich (Ireland). A 168 
sample of Labrasol (Caprylocaproyl polyoxyl-8 glycerides), Labrafil M1944 CS (Oleoyl 169 
polyoxyl-6 glycerides), Labrafil M2125 CS (Linoleoyl polyoxyl-6 glycerides), Plurol Oleique 170 
CC 497 (Polyglyceryl-3 dioleate) and Gelucire 44/14 (Lauroyl polyoxyl-32 glycerides) was 171 
kindly donated by Gattefossé (France). A sample of Cremophor EL (Polyoxyl 35 castor oil) 172 
was kindly donated by BASF (Germany). All other chemicals and solvents were of analytical 173 
or high-performance liquid chromatography (HPLC) grade and were purchased from Sigma-174 
Aldrich (Ireland) and used as received. 175 
 176 
Solubility studies 177 
Equilibrium solubility at 37 °C was determined in Tween 20, Tween 85, Labrasol, Labrafil 178 
M1944CS, Span 80, Cremophor RH40, Brij O2, Brij L23, and in a Tween 85/Cremophor RH40 179 
mixture (67:33 w/w) in order to represent the formulations that were used during in vitro 180 
lipolysis and the in vivo study. Solid excipients were melted at 50 °C and cooled to 37 °C, while 181 
liquid surfactants were heated to 37 °C before addition of excess nilotinib. The suspensions 182 
were stirred at 250 rpm and 37 °C. Samples were taken after 24 h, 48 h, 72 h and centrifuged 183 
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at 21,380g  and 37 °C for 15 min (Mikro 200 R, Hettich GmbH, Germany). The supernatant 184 
was transferred to a new tube and centrifuged again under identical conditions. To solubilise 185 
the surfactants, the supernatant was diluted in acetonitrile, ethyl acetate (1:4, v/v). Followed by 186 
further 1:10 (v/v) dilution with acetonitrile, ethyl acetate (4:1). The obtained samples were 187 
diluted appropriately with mobile phase before analysis by reverse phase HPLC. Equilibrium 188 
was assumed once two time-points did not differ more than 10%. All samples were run in 189 
triplicates.  190 
 191 
The samples were analysed as described previously. 24 In brief, an Agilent 1200 series HPLC 192 
system comprised a binary pump, degasser, autosampler and variable wavelength detector. 193 
Data analysis was done with EZChrom Elite version 3.2. Nilotinib was separated with a Zorbax 194 
Eclipse Plus-C18 column (5 μm, 4.6 mm x 150 mm) including a Zorbax Eclipse Plus-C18 195 
guard column (5 μm, 4.6 mm x 12.5 mm) at 25 °C. The mobile phase consisted of acetonitrile, 196 
methanol, water and triethylamine (35:30:34:1 v/v) and was used at a flow rate of 0.9 mL/min. 197 
20 μL samples were injected and the detection wavelength was 267 nm. The limit of detection 198 
(LOD) and limit of quantification (LOQ) of this method was 4 ng/mL and 12 ng/mL, 199 
respectively. Values were determined using the standard error of y-intercept according to the 200 
ICH Q2 guideline 42 and linearity was confirmed between 12 ng/mL and 12 μg/mL drug 201 
concentration. 202 
 203 
In vitro lipolysis: Digestibility and drug solubilisation during formulation dispersion and 204 
digestion 205 
In vitro lipolysis was studied using a pH-stat apparatus (Metrohm AG, Herisau, Switzerland) 206 
comprising a Titrando 907 stirrer, 804 Ti-stand, a pH electrode (Metrohm, Herisau, 207 
Switzerland) and two 800 Dosino dosing units coupled to a 20 mL autoburette. The system was 208 
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operated by the Tiamo 2.2 software. The in vitro protocol was amended from Williams et al. 209 
43, 44 In brief, the buffer contained 2 mM TRIS maleate, 150 mM NaCl, 1.4 mM CaCl2·2H2O, 210 
adjusted to pH 6.5. For the digestion experiments the buffer was supplemented with 3 mM 211 
NaTDC and 0.75 mM PC and stirred for 12 hours before further usage. The pancreatin extract 212 
was prepared freshly by adding 5 mL of 5 °C buffer to 1 g of porcine pancreatic enzymes (8x 213 
USP), which was vortexed thoroughly. The mixture was centrifuged for 15 min at 5 °C, 2800g 214 
(Hettich Rotina 380R) and 4 mL of supernatant was recovered and stored at 2 – 8 °C before 215 
further usage. The pancreatic extract had a pancreatic lipase activity of ∼10 000 TBU/mL (to 216 
provide approximately 1000 TBU per mL of digest), where 1 TBU represents the amount of 217 
enzyme that liberates 1 µmol of FA from tributyrin per min. 45 All experiments were conducted 218 
with a stirring speed of 450 rpm. 219 
 220 
For the digestibility study, 1.0 g of blank excipient was dispersed into 36 mL of digestion 221 
buffer. The pH was adjusted to 6.5 using 0.2 M, 0.6 M or 1 M NaOH depending on the pH 222 
change upon excipient addition. Digestion was initiated by the addition of 4 mL pancreatic 223 
enzyme and the pH of 6.5 was maintained using 0.2 M and 0.6 M NaOH for long and medium 224 
chain excipients, respectively. After 60 min of digestion the enzymes were inhibited using 1 M 225 
4- bromophenylboronic acid in methanol (5 μL per mL media) and the pH was increased to 226 
9.0. An additional blank titration using solely the digestion buffer was performed and the 227 
released mmol of FFAs from the blank was subtracted from the mmol of FFAs released from 228 
the surfactant formulations. The determined amount of FFA was assumed as a surrogate 229 
parameter for digestibility. Additionally, the % digested was calculated using the theoretical 230 
released FFAs per g of excipient: 231 
𝑇𝑇ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝐹𝐹𝐹𝐹𝐹𝐹 [𝑚𝑚𝑚𝑚𝑒𝑒𝑒𝑒] = 𝑆𝑆𝑆𝑆 [𝑚𝑚𝑚𝑚]
56.1056 [ 𝑔𝑔𝑚𝑚𝑚𝑚𝑚𝑚]
   (1) 232 
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where FFA are the FFAs that can theoretically be released from the excipient in mmol per g of 233 
excipient, SV the saponification value in mg KOH per g of excipient from the certificate of 234 
analysis and 56.1056 g/mol the molecular weight of KOH. The absolute amount of theoretical 235 
possible released mmol FFA can be calculated by multiplying by the amount of excipient used 236 
in this study, i.e 1.0 g. The % digested can be calculated as follows: 237 
% 𝑑𝑑𝑒𝑒𝑑𝑑𝑒𝑒𝑑𝑑𝑒𝑒𝑒𝑒𝑑𝑑 = 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝐹𝐹𝐹𝐹𝐹𝐹 [𝑚𝑚𝑚𝑚𝑚𝑚𝑅𝑅]
𝑇𝑇ℎ𝑅𝑅𝑚𝑚𝑒𝑒𝑅𝑅𝑒𝑒𝑒𝑒𝑒𝑒𝑅𝑅𝑅𝑅 𝐹𝐹𝐹𝐹𝐹𝐹 [𝑚𝑚𝑚𝑚𝑚𝑚𝑅𝑅]
× 100 %  (2) 238 
where the released FFA are the total mmol of FFA released in the digestibility experiment 239 
(including the amount detected during back titration to pH 9.0) and theoretical FFA the total 240 
mmol of FFA calculated with equation 1.  241 
 242 
For the in vitro lipolysis experiment with nilotinib 1.075 g of lipid formulation was dispersed 243 
into 39 mL of digestion buffer for 10 min. Three 1 mL samples were taken at 2.5, 5 and 10 min 244 
from the middle of the vessel. pH of the media was adjusted and maintained at 6.5 using 0.2 M 245 
NaOH and 0.6 M NaOH for medium and long chain excipients, respectively. To the remaining 246 
36 mL (1 g lipid formulation) dispersion 4 mL of pancreatin extract was added to initialize 247 
digestion. After 60 min the released non-ionized FFAs were determined by a pH increase of 248 
the buffer to pH 9.  249 
 250 
Samples of 1 mL were taken at 5, 10, 15, 30, 45 and 60 min during the digestion experiment 251 
from the middle of the vessel. In each sample and after 60 min the enzymes were inhibited by 252 
the addition of 1 M 4-bromophenylboronic acid in methanol (5 μL per mL sample). 253 
Additionally, to each 1 mL sample during digestion a 100 µL sample was taken and added to 254 
900 µL of acetonitrile and methanol (35:30 v/v) and mixed. This sample was used to quantify 255 
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the total drug recovery, which allowed adjustments of inhomogeneous samples. All samples 256 
were centrifuged at 37 °C and 21,000g for 30 min (Hettich Micro 200R).  257 
 258 
Formulations for in vivo and in vitro studies 259 
The solubility of nilotinib in the studied surfactants was low resulting in high dose solubility 260 
ratios (Table 1) and therefore it was not possible to prepare surfactant solutions at the target 261 
dose. It was hence decided to use surfactant suspensions for all experiments, keeping the 262 
surfactant and dose load constant. The surfactant suspensions were prepared by combining 10 263 
mg nilotinib with 1 mL surfactant excipient followed by an over-night stir at 37 ⁰C resulting in 264 
varying fractions of pre-dissolved nilotinib (Table 1). The suspensions were stirred constantly 265 
to prevent sedimentation before usage. Solid excipients were melted prior to nilotinib addition 266 
and kept in a liquid form while stirring, addition and in vivo administration. 267 
  268 
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Table 1 Dose:solubility ratio of studied surfactant formulations. The dose was fixed at  269 
10 mg/mL. 270 
Formulations for in vitro and in vivo studies 
Excipient Dose:solubility ratio 
Span 80 17.86 
Brij O2 14.49 
Labrafil M1944 CS 11.36 
Tween 85 7.87 
Tween 85/ Cremophor RH40 67:33 (w/w) 5.32 
Tween 20 4.83 
Brij L23 4.69 
Cremophor RH40 2.94 
Labrasol 2.43 
 271 
In vivo study 272 
The protocol used for the in vivo pharmacokinetic study was approved by the institutional 273 
animal ethics committee in accordance with Belgian law regulating experiments on animals 274 
and in compliance with EC directive 2010/63/EU and the NIH guidelines on animal welfare. 275 
Male Sprague-Dawley rats weighing 280-320 g (8-10 weeks of age) on the day of the 276 
experiments were purchased from Charles River Laboratories Deutschland (Sulzfeld, 277 
Germany) and maintained on standard food and water ad libitum in the laboratory for at least 278 
5 days before entering the experiment. Food was removed 16-20 h before dosing and water 279 
was available ad libitum at all times. Parallel groups of animals were administered with each 280 
formulation at a volume of 2 mL/kg by oral gavage with a nilotinib dose of 20 mg/kg. By 281 
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individual tail vein puncture, 200 µL blood samples were collected into plasma collection tubes 282 
containing dipotassium EDTA. Samples were taken at 0.5, 1, 2, 4, 6, 8, 10 and 24 h following 283 
oral dosing. Plasma was harvested immediately by centrifugation for 10 min at 1,000 g and 284 
stored at -80 °C until analysis. After the experiment the animals were euthanized. 285 
 286 
Bioanalysis 287 
The plasma concentrations of nilotinib were determined by reversed phase HPLC. The Agilent 288 
1260 series HPLC system comprised a binary pump, degasser, temperature controlled 289 
autosampler, column oven and diode array detector. The system was controlled, and the data 290 
analysed with EZChrom Elite version 3.3.2. The used method was described earlier. 24 In brief, 291 
a Zorbax Eclipse Plus-C18 column (5 μm, 4.6 mm x 150 mm) with a Zorbax Eclipse Plus-C18 292 
guard column (5 μm, 4.6 mm x 12.5 mm) was used. The mobile phase consisted of water, 293 
methanol, acetonitrile and triethylamine (34:30:35:1 v/v) and was used at a flow rate of 0.9 294 
mL/min. The sample and column temperature were set at 5 °C and 25 °C, respectively, and the 295 
detection wavelength was 267 nm. Nilotinib was extracted from the plasma samples by liquid-296 
liquid extraction. To 50 μL of the plasma sample 66 μL of a methanol acetonitrile mixture 297 
(30:35 v/v), containing 1.25 μg/mL sorafenib as internal standard, was added. The mixture was 298 
mixed thoroughly and centrifuged at 22 °C, 11,500g for 9 min. 50 μL of the supernatant was 299 
injected to the HPLC system for analysis. The LOD and LOQ values of this method in plasma 300 
were 11 ng/mL and 37 ng/mL, respectively, as determined using the standard error of y-301 
intercept according to the ICH Q2 guideline. 42 Linearity was confirmed between 37 ng/mL 302 




Data Analysis 305 
The pharmacokinetic parameters were calculated using Microsoft Excel. The plasma 306 
concentration profiles were analysed by non-compartmental analysis and calculation of AUC 307 
by the linear trapezoidal rule. Absolute bioavailability was calculated using previous reported 308 
intravenous data. 46 The statistical analysis for all in vivo parameters was performed using a 309 
one-way analysis of variance (one-way ANOVA) after using the Bartlett’s test to check for 310 
equal variance. Groups were pairwise compared using Tukey’s multiple comparison test.  311 
A one-way ANOVA was also calculated for the lipolysis data using the Tukey post-hoc test to 312 
compare the different formulation performances. All statistical analyses were carried out using 313 
GraphPad Prism 5. 314 
 315 
RESULTS 316 
Ranking the digestibility of lipid-based surfactants  317 
The digestibility of 15 surfactants and one surfactant blend commonly used in oral drug 318 
formulations was assessed using the in vitro lipolysis model. A variety of both medium and 319 
long chain FA were selected, with HLB values ranging from 2 to 17. The studied surfactants 320 
included stearate, oleate or palmitate, which were considered as long chain FA. Surfactants 321 
consisting of FAs like caprylic, capric or lauric acid were considered as medium chain 322 
excipients. The FFA based digestibility is shown in Figure 1 A and the % digested based 323 





Figure 1. Surfactant digestibility in the in vitro lipolysis test. Tween/Cremophor is a mixture 327 
of Tween 85 and Cremophor RH40 at a ratio of 67:33 (w/w). The shaded area represents long 328 
chain excipients and non-shaded areas represent medium chain excipients. The numbers above 329 
the bars are the corresponding HLB values of the surfactants. Data is presented as mean ± SD, 330 
where n=3. A: Free fatty acids (FFA) released. The total FFA released is divided into the 331 
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amount of FFA released during pH stat titrated directly at pH 6.5 (white bars) and the 332 
determined amount of FFA during increase of the pH to pH 9.0 after 60 min of digestion (back 333 
titration, dotted bars). B: % digested based on the theoretical possible amount of FFA release.  334 
 335 
In general, medium chain-based surfactants displayed the highest quantity of FFA released. 336 
Labrasol, a medium chain excipient mainly consisting of PEG-8 mono- and diesters of caprylic 337 
and capric acid showed the highest release of FFA (Figure 1 A). Gelucire 44/14, which is 338 
composed of mostly PEG-32 mono- and diesters of lauric acid, showed the second highest 339 
amount of released FFA. Tween 20, a polyoxyethylene sorbitan monoester of lauric acid, 340 
released 0.63 ± 0.04 mmol of FFA (Figure 1 A), which reflected a theoretical digestion of 76% 341 
(Figure 1 B). Brij L23, a polyoxyethylene lauryl ether, was included as a negative control, as 342 
the ether cannot be digested by lipases (a subclass of esterases) 47, 48 and therefore, showed the 343 
expected absence of FFA release.  344 
 345 
Among the long chain surfactants, Labrafil M1944 CS, which consists of mono-, di- and 346 
triglycerides and PEG-6 mono- and diesters of oleic acid, showed the highest released FFA 347 
(Figure 1 A). Considering the theoretically possible digestion, only 33.8 ± 1.0% of Labrafil 348 
M1944 CS was digested (Figure 1 B). The highest % digested was shown for Tween 80, a 349 
surfactant that like Labrafil M1944 CS also contains oleic acid (Figure 1 B). While the 350 
lowest % digested was observed for Span 85 (Figure 1 B), the lowest amount of FFA was 351 
released in the case of Cremophor RH40 (Figure 1 A). This finding agreed with previous 352 
studies that demonstrated a low release of FFAs as well as theoretical digestibility of 353 
Cremophor RH40. 49, 50 Brij O2, a polyoxyethylene oleyl ether, did not undergo digestion and 354 
was included as a negative control. In fact, long chain surfactants were digested to a lesser 355 
extent compared to medium chain surfactants. 356 
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Based on the digestibility properties observed, surfactants with a range of digestibility, HLB 357 
value and chain length were selected for further in vitro and in vivo investigations. The study 358 
design allowed the evaluation of the influence of digestion, HLB value and FA chain length on 359 
the formulation performance in vivo (Figure 2). In terms of ranking digestibility, FFA released 360 
was chosen as a surrogate parameter for how much the system is changing over time rather 361 
than the % digested, as surfactants can show inhibitory effects on lipolysis and the excipient 362 
and its lipolytic products can exhibit different activities on the digestive enzymes. 51, 52 363 
Especially in cases with a high amount of possible released FAs the adjustment to % digested 364 
may lack information on the amount of liberated FA, which are crucial for the beneficial 365 
solubilising and biopharmaceutical effects. Labrasol, Labrafil M1944 CS, Tween 20, Span 80, 366 
Brij L23 and Brij O2 were selected as the digestibility was matching with the chain length and 367 
HLB value, respectively. Additionally, the two widely used surfactants Tween 85 and 368 
Cremophor RH40, as well as a 2:1 (w/w) mixture of both, were included in the in vivo study. 369 
The study design is shown in Figure 2 and the surfactant properties in Table 2.  370 
 371 
Figure 2. Selected excipients for further in vitro and in vivo evaluation. Excipients were 372 
selected according to the fatty acid chain length, HLB and total free fatty acids (FFA) released 373 




Comparing nilotinib solubility as a function of lipid-based surfactant type 376 
The solubility of nilotinib in all selected excipients was measured at 37 ⁰C. The results of the 377 
solubility studies are presented in Table 2 and Figure S 1 in the supporting information. 378 
Nilotinib displayed the highest solubility in Labrasol and the lowest in Span 80. There were no 379 
apparent trends in relationship between solubility and either the FA chain length nor HLB 380 
value.  381 
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Table 2. Surfactant properties, solubility of nilotinib in surfactants, nilotinib solubilisation in the aqueous phase of the in vitro lipolysis test after 60 382 
min, FFA released and % digested after 60 min of digestion and absolute bioavailability of nilotinib formulations in male Sprague-Dawley rats (mean 383 
±SD, n = 3, except in vivo, where n = 5). The table is sorted according to the in vivo absolute bioavailability from high to low.  384 












[mmol] % digested 
Tween 20 MC 16.7 2.07 ±0.22 1.76 ± 0.11 66.50 ± 21.96 0.63 ± 0.04 75.78 ± 4.25 
Labrasol MC 12 4.12 ± 0.05 0.66 ± 0.07 33.82 ± 11.52 1.69 ± 0.02 91.81 ± 0.98 
Labrafil M1944 CS LC 9 0.88 ± 0.45 0.45 ± 0.08 26.02 ± 6.86 0.99 ± 0.03 33.82 ± 1.04 
Span 80 LC 4.3 0.56 ± 0.03 1.12 ± 0.09 25.99 ± 11.48 0.51 ± 0.02 19.09 ± 0.85 
Cremophor RH40 LC 15 3.40 ± 0.41 11.07 ± 1.40 22.83 ± 10.00 0.22 ± 0.01 22.61 ± 1.25 




LC 12.3 1.88 ± 0.08 6.94 ± 0.52 17.08 ± 5.62 0.38 ± 0.01 27.33 ± 0.97 
Brij L23 MC 16.9 2.13 ± 0.03 11.80 ± 1.78 16.71 ± 5.27 0.00 ± 0.01 0.00 ± 0.00 
Brij O2 LC 4.9 0.69 ± 0.04 0.19 ± 0.05 7.32 ± 3.87 - 0.05 ± 0.02 0.00 ± 0.00 
a) MC: medium chain, LC: long chain  385 
b) Aqueous phase concentration in the in vitro lipolysis test after 60 min of digestion 386 
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Comparing nilotinib solubilisation following in vitro dispersion and digestion. 387 
A range of surfactant-based formulations containing 10 mg/mL nilotinib were prepared and 388 
assessed in the in vitro dispersion/lipolysis test. The release and dissolution of nilotinib into the 389 
different phases were monitored during dispersion and 60 min of digestion. The concentration 390 
of nilotinib in the aqueous phase is shown in Figure 3 and Table 2, the distribution across all 391 
phases before initiation of digestion (0), 30 min and 60 min after digestion is shown in  392 
Figure S 2 in the supporting information and the FFA released versus time profiles in  393 
Figure S 3 in the supporting information. 394 
 395 
 396 
Figure 3. Aqueous phase concentration during 60 min of in vitro lipolysis of selected nilotinib 397 
suspensions. Cremophor RH40 (◊), Brij L23 (*), Tween 20 (○), Span 80 (▲), Labrasol (■), 398 
Labrafil M1944 CS (□), Tween 85 (●), Brij O2 (×), Tween 85/Cremophor RH40 mixture (67:33 399 
w/w) (▼) (mean ± SD, n = 3). 400 
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All formulations displayed good dispersion characteristics upon addition to the media. The 401 
highest concentration of nilotinib upon dispersion was observed for Cremophor RH40 with 16 402 
± 1% of the dose dissolved in the aqueous phase. This was followed by Brij L23 with 14 ± 2% 403 
of dissolved nilotinib in the aqueous phase. Approximately 6 - 8% of the nilotinib dose was 404 
dissolved in the case of Labrasol, Tween 20, Tween 85 and the Tween 85/Cremophor RH40 405 
mixture, which was mid-range relative to the other tested formulations. Poor solubilisation was 406 
observed for Span 80, Brij O2 and Labrafil M1944 CS with concentrations < 1%.  407 
 408 
Upon initiation of digestion Cremophor RH40 and Brij L23 were able to maintain relatively 409 
high concentrations for 15 min followed by a decrease in concentration to 11 ± 1% at 30 min, 410 
which was maintained throughout the rest of digestion. The Tween 85/Cremophor RH40 411 
mixture and Tween 85 maintained the initial dispersion concentration throughout digestion. 412 
Labrasol and Tween 20 showed an initial drop in concentration and a further decrease 413 
throughout the 60 min resulting in concentrations below 2%. The surfactants that demonstrated 414 
very low nilotinib concentrations < 1% upon dispersion also maintained the low concentrations 415 
throughout digestion. The ranking of the nilotinib concentration in the aqueous phase upon 416 
dispersion was Cremophor RH40 ≥ Brij L23 > Tween 20 ≥ Labrasol ≥ Tween 85 ≥ Tween 417 
85/Cremophor RH40 > Span 80 ≥ Labrafil M1944 CS > Brij O2. After 60 min of digestion the 418 
aqueous phase concentration of nilotinib was ranked Brij L23 ≥ Cremophor RH40 > Tween 419 
85/Cremophor RH40 mixture ≥ Tween 85 > Tween 20 ≥ Span 80 ≥ Labrasol ≥ LabrafilM 1944 420 
CS ≥ Brij O2. Overall, there was no apparent relationship between the ranking in solubilisation 421 
capacity and surfactant HLB FA chain length or digestibility. 422 
 423 
In order to gain insights into the nilotinib distribution post-digestion, all samples were separated 424 
into three different phases (solid, aqueous and lipid phase) by centrifugation (Figure S 2). The 425 
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solid phase represents the undissolved crystalline drug within the surfactant formulation and all 426 
formulations showed the highest amount of nilotinib in the solid phase. Additionally, in the 427 
case of Labrafil M1944 CS, Span 80 and Brij O2 an oily phase was detected throughout 428 
digestion. In all cases the concentration of nilotinib increased in the oily phase as digestion 429 
progressed.  430 
 431 
Ranking the in vivo bioavailability of surfactants 432 
The in vivo performance of nilotinib surfactant formulations was evaluated in male Sprague-433 
Dawley rats. An aqueous suspension containing 0.5% (w/v) methylcellulose (for stabilisation) 434 
was used as a non-surfactant control formulation, as previously described. 46 The absolute 435 
bioavailability is shown in Figure 4, the plasma concentration versus time profiles are presented 436 
in Figure S 4 in the supporting information and the pharmacokinetic parameters in Table 3. 437 
 438 
 439 
Figure 4. Absolute bioavailability (Fabs) of nilotinib suspensions in male Sprague-Dawley rats 440 
after oral administration of 20 mg/kg nilotinib and 2 mL/kg excipient in comparison to an 441 
aqueous suspension, as previously described. 46 Tween 20 is significantly different to all other 442 
tested surfactants and the aqueous suspension. Tween/Cremophor is a mixture of Tween 85 and 443 
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Cremophor RH40 (67:33 w/w). Shaded area represents long chain excipients and non-shaded 444 





Table 3. Pharmacokinetic parameters of nilotinib after oral administration of 20 mg/kg nilotinib and 2 mL/kg excipient to male Spraque-Dawley rats. 448 
Nilotinib was administered as surfactant suspensions (n = 5). tmax, mean residence time (MRT) and mean absorption time (MAT) are given as median 449 
(range), all other parameters as mean ± SD.  450 
 
Pharmacokinetic parameters 
 AUC 0 h – inf. 
[μg*h/mL] cmax [µg/mL] tmax [h] MRT [h] MAT [h] Fabs [%] 
b) 
Aqu. susp.a) 14.33 ± 4.24 2.65 ± 0.68 2 (2-4) 4.14 (3.34 – 4.83) 2.49 (1.69 – 3.18) 12.90 ± 3.34 
Tween 20 73.89 ± 24.40 10.28 ± 3.64 2 (2-6) 5.59 (4.97-6.96) 3.94 (3.32-5.32) 66.50 ± 21.96 
Tween 85 21.54 ± 7.66 3.13 ± 0.84 4 (2-4) 6.05 (4.56-6.29) 4.40 (2.91-4.64) 19.38 ± 6.89 
Labrasol 37.59 ±12.80 4.76 ± 1.83 10 (6-10) 7.62 (6.35-8.00) 5.97 (4.70-6.35) 33.82 ± 11.52 
Labrafil M1944 CS 28.91 ±7.63 4.18 ± 1.00 8 (4-10) 7.50 (6.03-8.50) 5.86 (4.38-6.85) 26.02 ± 6.86 
Cremophor RH40 25.37 ± 11.11 3.43 ± 1.40 10 (2-10) 7.56 (4.46-7.65) 5.92 (2.82-6.00) 22.83 ± 10.00 
Span 80 28.88 ± 12.75 4.30 ± 2.23 8 (8-10) 7.88 (6.65-8.41) 6.23 (5.00-6.77) 25.99 ± 11.48 
Brij O2 8.14 ± 4.30 0.98 ± 0.38 4 (1-8) 5.99 (4.58-6.76) 4.35 (2.94-5.12) 7.32 ± 3.87 
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Brij L23 18.57 ± 5.85 2.77 ± 1.31 10 (6-10) 7.50 (7.26-8.31) 5.85 (5.61-6.67) 16.71 ± 5.27 
Tween 
85:Cremophor 
RH40 (67:33 w/w) 
18.98 ± 6.24 2.93 ± 1.01 4 (2-8) 5.70 (5.43-7.49) 4.05 (3.78-5.84) 17.08 ± 5.62 
a) Data as previously described by Koehl et al. 46 451 
b) Intravenous data obtained from Koehl et al. 46452 
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Interestingly, the highest exposure was observed for the medium chain surfactant Tween 20 453 
with an absolute nilotinib bioavailability of 66.5 ± 22.0%. This was statistically significant 454 
higher compared to all other study arms and the aqueous suspension (p < 0.05). The Labrasol 455 
formulation increased bioavailability to 33.8 ± 11.5%, which was significantly higher relative 456 
to the Brij O2, a non-digestible formulation. While there was a trend towards an increased 457 
bioavailability for the Labrasol formulation compared to the aqueous suspension, the increases 458 
did not reach statistical significance. In contrast, the Brij O2 formulation showed a trend 459 
towards a decreased bioavailability of 7.3 ± 3.9% compared to the aqueous suspension, 460 
although not statistically significant. All other formulations (Brij L23, Tween 85/Cremophor 461 
RH40 mixture, Tween 85, Cremophor RH40, Span 80, Labrafil M1944 CS and the aqueous 462 
suspension) displayed similar in vivo bioavailability of between 16.7 ± 5.3% to 26.0 ± 6.9%.  463 
 464 
Relationship between surfactant digestibility and in vivo bioavailability 465 
The surfactant properties were compared to the absolute bioavailability obtained in the in vivo 466 
study. Surfactants with different HLB values resulted in a similar absolute bioavailability. 467 
Therefore, no relationship between the in vivo performance and the HLB value was established. 468 
While the two top performing surfactants contain medium chain FA, the third lowest absolute 469 
bioavailability was observed for Brij L23, also containing medium chain FA. In the case of the 470 
digestion independent Brij L23, however, the FA was not released. The results, therefore, 471 
indicate that in terms of released FA during digestion the in vivo performance might be related 472 
to FA chain length. The most promising in vitro-in vivo-relationship was observed between 473 
surfactant digestibility and the in vivo bioavailability. Figure 5 displays the absolute 474 
bioavailability versus % digested and Figure S 5 in the supporting information shows absolute 475 
bioavailability versus FFA released. The strongest trend was observed between the absolute 476 
bioavailability and the % surfactant digested (r2 = 0.5628). In the case of the in vitro-in vivo-477 
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relationship for the absolute bioavailability versus FFA released the overall trend was poor  478 
(r2 = 0.1811), which may reflect that overall the extent of surfactant digestion is more reliable 479 
representing the in vivo performance than the amount of FFA released.  480 
 481 
 482 
Figure 5. Absolute bioavailability (Fabs) versus % digested of Cremophor RH40 (◊), Brij L23 483 
(*), Tween 20 (○), Span 80 (▲), Labrasol (■), Labrafil M1944 CS (□), Tween 85 (●), Brij O2 484 
(×), Tween 85/Cremophor RH40 mixture (67:33 w/w) (▼) (mean ± SD, Fabs n = 5, % digested 485 
n = 3). 486 




Selection of surfactants during oral formulation development requires a in depth understanding 489 
of the surfactant characteristics both in vitro and in vivo. Non-ionic surfactants such as Tweens 490 
and Poloxamers are widely used excipients in commercial formulations to facilitate a higher 491 
dissolution rate and improve solubility. The solubilising effects are typically influenced by 492 
digestion and surface-active excipients can affect digestion itself. 51, 52 Surfactants may further 493 
affect drug permeation, drug efflux and potentially metabolism in enterocytes. 12, 13, 16, 21 494 
Surfactant selection in oral formulation is largely empirically driven, with limited consideration 495 
of the impact of surfactant properties or likely surfactant digestion on the in vivo performance. 496 
This study, therefore, addresses the need for a systematic comparison of surfactant digestibility 497 
and assessment of surfactant properties on in vivo performance using nilotinib as a model poorly 498 
water-soluble compound.  499 
 500 
To the best of our knowledge, this is the first study to compare digestibility of a range of 15 501 
commonly used surfactants and hence this allows the establishment of a digestibility databank 502 
for surfactants. Overall, the findings suggested that surfactants containing medium chain FAs 503 
displayed a higher digestibility compared to surfactants containing long chain FAs. This finding 504 
agrees with previous reports of smaller sets of surfactants 49 as well as glycerides 53 and lipid 505 
formulations. 43 The lower digestibility of surfactants containing long chain FAs can be 506 
attributed to the extent of long chain FA ionisation 43, 54 and the limited solubilisation capacity 507 
of the digestion media for the long chain FAs. 43, 53 Long chain FAs are ionised to a lower extent 508 
relative to medium chain FAs at the pH of 6.5. 43, 53 Therefore, the non-ionised long chain FAs 509 
are in need of micellar solubilisation due to a poor solubility in the digestion media. Once the 510 
solubilisation capacity of the digestion media for long chain FAs is reached, the long chain FAs 511 
accumulate at the droplet/micellar interface, effectively inhibiting further enzyme binding and 512 
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digestion. 43 In addition, the analysis of the surfactant digestibility revealed that digestibility 513 
was not influenced by the HLB value. This indicates that surfactant digestibility was not readily 514 
predictable and highlights the importance of in vitro lipolysis in the characterisation and 515 
selection of surfactants in oral dosage forms. It should also be acknowledged that the reported 516 
in vitro digestibility (FFA released and % digested) might not be entirely translatable to an in 517 
vivo digestibility, as non-ionic surfactants and their lipolytic products can inhibit digestion in 518 
vitro depending on the given conditions. For example, Cremophor RH40, Cremophor EL, 519 
Tween 80, Tween 20 and Brij L23 are known to inhibit digestion to varying extents 51, 55, 56 520 
leading to a lower or slower 57 digestion compared to in vivo, where the inhibiting surfactants 521 
and their lipolytic products could be absorbed. Additionally, the type of enzyme or enzymatic 522 
extract as well as pH of the media has been shown to influence the enzymatic activity and 523 
consequently the overall extent of digestion, as shown for the excipient Labrasol. 52 Thus, the 524 
total amount of released FFA and/or a given % digested depends on the employed in vitro or in 525 
vivo system. 526 
 527 
Among the surfactants, the highest absolute bioavailability was observed for the medium chain 528 
excipients Tween 20 (Fabs 66.50 ± 21.96%), which was statistically significant higher compared 529 
to all other surfactants (p < 0.05). The second highest bioavailability was observed for the 530 
medium chain surfactant Labrasol, which was statistically significant higher compared to Brij 531 
O2 (p < 0.05). Both Tween 20 and Labrasol are digestible medium chain-based surfactants 532 
indicating that the in vivo performance might be influenced by the release of medium chain FA. 533 
In terms of the HLB value, a relationship to the in vivo performance was not apparent. 534 
Additionally, the in vivo performance was not influenced by the solubility of nilotinib in the 535 
excipients. For example, even though the dose-solubility ratio for Brij L23 (4.7) and Tween 20 536 
(4.8) were similar, the bioavailability was significantly higher for the Tween 20 formulation. 537 
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This suggests that the solubility in the surfactants was not a limiting factor to the oral 538 
bioavailability.  539 
 540 
Interestingly, the study suggested that the in vivo exposure was influenced by the digestibility 541 
of the surfactants, and in general highly digestible surfactants such as Labrasol, Tween 20 and 542 
Labrafil M1944 CS displayed the highest bioavailability. Similarly, the two least digested 543 
surfactants Brij L23 and Brij O2 showed the lowest bioavailability, which may suggest that the 544 
drug was trapped within the non-digestible surfactant micelles. This finding is in line with the 545 
observation by Berthelsen and co-workers where bioavailability did not increase with 546 
increasing surfactant concentration due to an entrapment in Cremophor RH40 micelles (which 547 
displayed lower digestibility relative to Cremophor EL). In contrast, in the case of the 548 
Cremophor EL surfactant micelles, which displayed higher digestibility, bioavailability 549 
increased with increasing surfactant concentration. 50 It should also be noted that it has been 550 
reported in the literature that surfactant only formulations of either Cremophor RH40 or EL did 551 
not lead to significant differences in bioavailability of danazol in dogs. 49 On the contrary, when 552 
incorporating surfactants into self-emulsifying lipid-based formulations, the poorly digestible 553 
surfactant Cremophor RH40 (55% w/w) displayed higher oral bioavailability of danazol 554 
compared to Cremophor EL (55% w/w). Possible reasons for this differing outcome between 555 
studies, may reflect the differing role of surfactant between different formulation types. 556 
Specifically, in the case of self-emulsifying systems, the surfactants also serve to support self-557 
emulsification and stabilisation of the emulsified oil phase. As such, digestion of surfactants 558 
may lead to destabilisation of the emulsion droplet, leading to drug precipitation. Therefore, for 559 
oil containing self-emulsifying formulations, it appears that low digestibility surfactants are 560 
favoured to improve emulsion stability during digestion and reduce the risk of drug 561 
precipitation from the oil droplets during lipolysis. However, our study confirmed that in the 562 
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case of nilotinib surfactant only systems, low digestibility surfactants may have led to lower 563 
overall in vivo exposure most likely via entrapment within surfactant micelles. 564 
 565 
Compared to the aqueous suspension, Tween 20 was the only surfactant that showed a 566 
statistically significant higher bioavailability. All other surfactants displayed a bioavailability 567 
between approximately 7.3% and 33.8%, which compared favourably to a previous report of 568 
nilotinib bioavailability of 34% in rats using a cremophor based micellar solution. 35 One 569 
explanation of the impressive in vivo performance of Tween 20 may be additional 570 
biopharmaceutical benefits of this excipient. In vitro cell assays have shown that Tween 20 is 571 
a P-gp (or MDR-1) inhibitor, 15, 16 reducing the efflux into the intestinal lumen. In the case of 572 
nilotinib transport by P-gp was demonstrated with an efflux ratio (basolateral/apical) of 3.9-4.1 573 
using Caco-2 cells. 35, 37, 38 This indicated that further P-gp inhibition by formulation excipient 574 
such as Tween 20 could have contributed positively to nilotinib’s bioavailability. A study by 575 
Cornaire et al. showed that the effectiveness to inhibit P-gp transport for digoxin was Labrasol > 576 
Imwitor 742 > Acconon E = Softigen 767 > Cremophor EL > Miglyol > Solutol HS 15 > 577 
Sucrose monolaurate > Tween 20 > TPGS > Tween 80 using the rat everted gut sac model. 58 578 
In addition, it was shown that Labrafil M1944 CS was not active as transport enhancer for 579 
digoxin. 58 P-gp as well as CYP3A4 share a significant overlap in substrate specificity, 59 which 580 
is also the case for nilotinib, which is mainly metabolised by CYP 3A4 in the enterocytes and 581 
liver. 35 In fact, co-administering nilotinib with grapefruit juice (intestinal CYP enzyme 582 
inhibitor) increased the AUC by 29% 39 showing a significant pre-systemic clearance. A study 583 
by Ren and co-workers showed that Tween 20 is a strong CYP 3A4 inhibitor using rat liver and 584 
intestinal microsomes. In comparison to the four tested non-ionic surfactants (Tween 20, 585 
Cremophor EL, Myrj S40 and Pluronic F68), Tween 20 was the most potent inhibitor. 586 
Additionally, the study confirmed a significant higher AUC for diazepam when co-587 
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administered with Tween 20 as well as a decrease in the metabolite (1-hydroxymidazolam) 588 
AUC to about 40%. 21 Therefore, the impact of Tween 20 on CYP 3A4 was more distinctive 589 
relative to P-gp and overall this would tend to suggest that the effect of CYP 3A4 is more 590 
relevant in the case of nilotinib, as also suggested by the significant increased bioavailability in 591 
the presence of grapefruit juice. 39 592 
 593 
During digestion FFAs are released, which generate a variety of colloidal species in 594 
combination with bile salts, phospholipids and lipolytic products, which potentially have a 595 
higher solubilisation capacity for drugs. For nilotinib it was previously shown that the solubility 596 
in post-digestive media of a lipid formulation was increased. 24 In addition, it was reported that 597 
the solubility of nilotinib is influenced by the bile salt concentration as evidenced by a higher 598 
solubility in FeSSIF (3.2 ± 0.1 µg/mL) compared to FaSSIF (0.3 ± 0.03 µg/mL). 24 As FFAs 599 
can increase the bile salt release in vivo, 60-62 digestion appears to be a crucial parameter for the 600 
success of the surfactant-only formulations. This was especially apparent for the digestible 601 
Tween 20 and non-digestible Brij L23, which both contain the medium chain FA lauric acid. 602 
The non-digestible formulation resulted in a significantly lower exposure indicating that the 603 
release of lauric acid may have been the driving factor for an improved bioavailability, as FFAs 604 
have also shown beneficial effects on drug permeability without pronounced cytotoxic effects. 605 
25, 28-30, 32, 33, 63-65 As nilotinib is passively transported, 66 the permeability enhancing effects of 606 
surfactants 12 and their lipolytic products may have contributed to a higher bioavailability of 607 
nilotinib when compared to the aqueous suspension.  608 
 609 
The in vitro lipolysis of Brij L23 and Cremophor RH40 formulations showed high 610 
concentrations of solubilised nilotinib in the aqueous phase upon dispersion and throughout 611 
digestion. For both surfactants a drop in nilotinib concentrations of approximately 4.9% after 612 
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15 min of digestion was observed. Similarly, the nilotinib aqueous phase concentration 613 
decreased in the case of Labrasol and Tween 20 upon initiation of digestion resulting in a total 614 
decrease of approximately 6.2% and 6.8%, respectively. However, the drop in nilotinib 615 
concentration in the aqueous phase did not seem to be exclusively related to the digestibility of 616 
these surfactants (Figure 1), as Labrasol and Tween 20 are highly digested, but Cremophor 617 
RH40 and Brij L23 are poorly or not digested. Furthermore, Labrafil M1944 CS and Tween 85, 618 
which are both rapidly and > 33% digested (Figure S 3, Figure 1), did not show a decrease in 619 
nilotinib concentration upon initiation of digestion. However, given that Tween 20 and Labrasol 620 
are both medium chain-based surfactants, it appears that the initial drop in nilotinib aqueous 621 
phase concentration upon initiation of digestion most likely reflects the combination of high 622 
digestibility and the release of medium chain FAs. This may reflect the lower solubilisation 623 
capacity of medium chain post digestive media, as previously reported. 67, 68 While there was 624 
no direct relationship between the HLB value of the surfactants and the performance in the in 625 
vitro lipolysis, there seemed to be a trend that surfactants with a HLB value > 10 performed 626 
better compared to surfactants with a HLB value < 10. For example, Brij L23 (HLB value: 16.9) 627 
showed an in vitro solubilisation of 11.8 ± 1.8%, whereas Brij O2 (HLB value: 4.9) only 628 
reached an in vitro solubilisation of 0.2 ± 0.1%. Surfactants with a HLB value > 10 are 629 
considered suitable for stabilising oil in water systems, whereas surfactants with a HLB value 630 
< 10 are suitable for stabilising water in oil systems. Thus, the higher HLB surfactants seem to 631 
stabilise solubilised nilotinib, which is highly lipophilic (logP: 4.95), in the aqueous phase 632 
better compared to low HLB surfactants. In contrast to the HLB value trend, the in vitro 633 
lipolysis test indicated that digestibility of the surfactants is not related to nilotinib solubilisation 634 
in the aqueous phase in vitro. For example, Brij L23 (non-digestible) and Cremophor RH40 635 
(digestible) demonstrated comparable aqueous phase concentrations but different digestibility. 636 
Additionally, no trend was established between the FA chain length and the aqueous phase 637 
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concentration of nilotinib. The aqueous phase concentration of the in vitro lipolysis is thought 638 
to represent the amount of drug readily available for absorption in vivo and is commonly used 639 
to rank formulation performances. However, due to the limitations of the in vitro systems, such 640 
as the lack of an absorptive sink, low media volume in combination with a high drug and 641 
excipient load as well as different hydrodynamics and enzyme activity compared to in vivo, a 642 
relationship between in vitro and in vivo performance for surfactants 49, 50 or other formulations 643 
24, 69, 70 has been reported difficult in some cases. Also, this study could not demonstrate a 644 
correlation between the aqueous phase concentration of the in vitro lipolysis test and the in vivo 645 
performance. For example, the relatively higher in vitro solubilisation of Brij L23 and 646 
Cremophor RH40 did not correlate with a higher in vivo performance, as bioavailability values 647 
of Cremophor RH40 and Brij L 23 were in the mid (approximately 23%) and low 648 
(approximately 17%) end of the range of absolute bioavailability obtained in vivo. An 649 
adjustment of the in vitro model to rat conditions (e.g. low enzyme activity and low 650 
gastrointestinal volumes), 71, 72 two stages (gastric and intestinal) 73-75 or the addition of an 651 
absorptive sink 76, 77 may offer additional insights into the in vivo behaviour.  652 
 653 
CONCLUSION 654 
The present study systematically investigated the relationship between non-ionic surfactant 655 
properties and the in vitro and in vivo performance using nilotinib. Tween 20 demonstrated an 656 
impressive 5.2-fold increase in absolute bioavailability when compared to an aqueous 657 
suspension. In general, surfactants that displayed high digestibility in vitro displayed higher 658 
nilotinib bioavailability in vivo. Medium chain FA-based surfactants appeared to be favourable 659 
to increase bioavailability compared to long chain FA types. However, HLB of the surfactant 660 
did not correlate with the in vivo performance of nilotinib. The reported additional 661 
biopharmaceutical effects of Tween 20, in terms of inhibition of CYP 3A4 and modulation of 662 
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P-gp efflux, may explain the impressive increase in bioavailability. Therefore, this study 663 
highlights the importance of appropriate surfactant selection to maximise in vivo exposure, with 664 
careful consideration of solubilisation properties, impact of digestion and biopharmaceutical 665 
effects. Further studies using broader range of drugs are therefore merited with the ultimate aim 666 
of developing a bio-predictive surfactant classification system.  667 
 668 
SUPPORTING INFORMATION  669 
Nilotinib solubility in studied excipients, distribution of nilotinib into different phases during 670 
in vitro lipolysis, FFA released versus time profiles during in vitro lipolysis, plasma 671 
concentration versus time profiles of nilotinib in rats, relationship of Fabs and FFA released. 672 
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